Animal Models of Emphysema

0
0
0

Animal Models of Emphysema

Introduction

Chronic obstructive pulmonary disease (COPD) is a major global health concern. It is characterized by not fully reversible airflow limitation and is mainly caused by cigarette smoke. Emphysema, a key pathological feature of COPD, leads to high mortality and significant medical costs. Understanding the mechanisms of COPD, including those related to emphysema, is crucial for developing effective treatments. Animal models play a vital role in this research as they help elucidate the cellular and molecular mechanisms involved in the pathogenesis of COPD.

Animal Selection for Modeling

A wide range of animals has been used to create emphysema models, such as sheep, dogs, pigs, rabbits, monkeys, guinea pigs, mice, rats, and squirrels. Each species has its own advantages and limitations. For example, rats have small body size, low breeding cost, and a short reproduction cycle, but they rely on nasal breathing and have poor respiratory function compared to humans. Pigs have more mature lung tissue and a similar lung structure to humans but have disadvantages like large body size and high cost. Mice are often considered a good choice as they have a genome similar to humans, and there are many strains available that respond differently to smoking. However, no animal model can perfectly replicate human COPD as there are differences in anatomy, physiology, and reactivity to various factors.

Mechanisms of Emphysema

  • Elastase-antielastase imbalance: In COPD, there is an imbalance between elastases (like those in the MMP family) and anti-elastases. Excessive elastases from inflammatory cells damage lung parenchyma, leading to emphysema. Genetic lack of alpha 1-antitrypsin (AT) is a direct example of this imbalance causing emphysema-like changes.
  • Oxidation-antioxidant imbalance: Oxidative stress is an important mechanism. Cigarette smoke and other harmful particles produce oxides that damage lung tissue and can cause protease-antiprotease imbalance. Antioxidants can alleviate COPD exacerbations and slow down lung function decline, indicating their role in the disease.
  • Inflammatory mechanism: Inflammation is central to COPD. When the respiratory tract’s defense mechanisms fail, foreign particles activate immune cells in the lung, releasing mediators like LTB4, IL-8, TNF-α, etc. These mediators damage lung tissue, promote neutrophil inflammation, and cause alveolar cavity enlargement.
  • Hormone related mechanism: COPD patients often show “hormone resistance,” and the mechanism is unclear. It may be related to the inactivation of the kB pathway or decreased histone deacetylase activity in the lung.
  • Immunologic mechanism: Macrophages and lymphocytes are involved. CD8+ lymphocytes play an important role, and the inflammatory response continues even after smoking cessation.
  • Vagus nerve stimulation: COPD patients have high airway reactivity and increased cholinergic nerve tension. This leads to bronchial smooth muscle contraction, gland hypersecretion, and airway remodeling, highlighting the significance of the cholinergic mechanism.

Modeling Methods of Animal Model of Emphysema

  • Elastase induced animal model: Elastase instillation disrupts protease-antiprotease balance. Commonly used elastases include papain, pig pancreatic elastinase (PPE), and human neutrophil elastease (HNE). For example, papain was used early to induce emphysema in rats, and PPE can act as both a protease and an oxidant. This method is simple but may not fully replicate human emphysema’s chronic process.
  • Passive smoking induced animal model: Smoking is a major risk factor for emphysema. Animal exposure to cigarette smoke (CS) can cause inflammatory responses in the lungs, similar to human smoking effects. Exposure methods include part (nose or head only) and whole body exposure. The guinea pig is sensitive to smoke, but the model’s experimental period is long and stability is poor.
  • Chemicals induced animal model: Many chemicals like NO2, LPS, O3, CdCl2, etc., can cause inflammation and emphysema. For instance, NO2 exposure can induce oxidative stress and emphysema in mice. LPS causes inflammation by stimulating immune cells.
  • Cigarette smoke extract induced animal model: Intraperitoneal injection of cigarette smoke extract (CSE) can produce emphysema in mice. It may act as an antigen to trigger an immune response. This method is relatively quick but may have extrapulmonary effects.
  • Other exogenous factors induced animal model: Severe hunger can cause emphysema-like changes due to accelerated metabolism of lung fibers, but it may not reflect the real human process and is rarely used.
  • Genetic manipulation in animal model: Gene knockout or overexpression can be used. For example, gene knockout mice like Abhd2 knockout mice show emphysema-like changes. Transgenic mice with overexpressed genes like PDGF-b can also display emphysema-like lesions.

Evaluation on Animal Model of Emphysema

After establishing the model, evaluation is needed. Parameters include pulmonary function indicators (e.g., airway resistance, lung dynamic compliance), airway inflammation indicators (cell counts, cytokine levels), oxidative stress indicators (like SOD, ROS), and pathomorphological indicators (mean linear intercept – MLI, destructive index – DI, apoptotic index – AI). While pulmonary function tests are important, pathomorphological indicators are considered the most crucial as they directly show the structural changes in the lung. According to the American Thoracic Society, emphysema is defined by abnormal alveolar enlargement and wall destruction. Pulmonary function tests may not be sensitive enough for mild emphysema, and quantitative assessment of micro-structure (like MLI, DI, AI) is key.

Summary and Prospect

Various animal models of emphysema exist, but none are perfect. Cigarette smoking-induced models are classic but have limitations. With the development of science and technology, more refined models are expected. Researchers should choose appropriate models based on experimental purposes and explore the pathogenesis through multiple methods. While mice are useful, differences between species must be considered. As research progresses, more standardized and reasonable animal models will likely be developed to better understand and treat COPD.

References

  1. Alfageme I, Reyes N, Merino M, Reina A, Gallego J, Lima J, et al. The effect of airflow limitation on the cause of death in patients with COPD. Chron Respir Dis 2010;7:135–145. doi: 10.1177/1479972310368692.
  2. Cavaillès A, Brinchaultrabin G, Dixmier A, Goupil F, Gutgobert C, Marchandadam S, et al. Comorbidities of COPD. Eur Respir Rev 2013;22:454–475. doi: 10.1183/09059180.00008612.
  3. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med 2017;195:557–582. doi: 10.1164/rccm.201701-0218PP.
  4. Buist AS, Mcburnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet 2007;370:741–750. doi: 10.1016/s0140-6736(07)61377-4.
  5. Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2013;381:1987–2015. doi: 10.1016/S0140-6736(13)61097-1.
  6. Patrick Mallia MD, Johnston SL. COPD: new treatment strategies. Future Prescriber 2013;14:13–16. doi: 10.1002/fps.104.
  7. Arne M, Lundin F, Boman G, Janson C, Janson S, Emtner M. Factors associated with good self-rated health and quality of life in subjects with self-reported COPD. Int J Chron Obstruct Pulmon Dis 2011;6:511–519. doi: 10.2147/COPD.S24230.
  8. Cho WK, Lee CG, Kim LK. COPD as a disease of immunosenescence. Yonsei Med J 2019;60:407–413. doi: 10.3349/ymj.2019.60.5.407.
  9. Dahl M, Nordestgaard BG. Markers of early disease and prognosis in COPD. Int J Chron Obstruct Pulmon Dis 2009;4:157–167. doi: 10.2147/copd.s3106.
  10. Andersen ML, Winter LMF, Andersen ML, Winter LMF. Animal models in biological and biomedical research – experimental and ethical concerns. An Acad Bras Cienc 2019;91:e20170238. doi: 10.1590/0001-3765201720170238.
  11. Mamoru T, Gen Y, Hiroyuki K, Hiroki T. Classification of centrilobular emphysema based on CT-pathologic correlations. Open Respir Med J 2012;6:155–159. doi: 10.2174/1874306401206010155.
  12. Ghorani V, Boskabady MH, Khazdair MR, Kianmeher M. Experimental animal models for COPD: a methodological review. Tob Induc Dis 2017;15:25. doi: 10.1186/s12971-017-0130-2.
  13. Jones B, Donovan C, Liu G, Gomez HM, Chimankar V, Harrison CL, et al. Animal models of COPD: what do they tell us? Respirology 2017;22:21–32. doi: 10.1111/resp.12908.
  14. Masaki F, Yoichi N. The pathogenesis of COPD: lessons learned from in vivo animal models. Med Sci Monit 2007;13:19–24. doi: 10.1051/medsci/2007232221.
  15. Abraham WM. Modeling of asthma, COPD and cystic fibrosis in sheep. Pulm Pharmacol Ther 2008;21:743–754. doi: 10.1016/j.pupt.2008.01.010.
  16. Chapman RW. Canine models of asthma and COPD. Pulm Pharmacol Ther 2008;21:731–742. doi: 10.1016/j.pupt.2008.01.003.
  17. Mata JF, Altes TA, Cai J, Ruppert K, Mitzner W, Hagspiel KD, et al. Evaluation of emphysema severity and progression in a rabbit model: comparison of hyperpolarized 3He and 129Xe diffusion MRI with lung morphometry. J Appl physiol 19852007;102:1273–1280. doi: 10.1152/japplphysiol.00418.2006.
  18. Plopper CG, Hyde DM. The non-human primate as a model for studying COPD and asthma. Pulm Pharmacol Ther 2008;21:755–766. doi: 10.1016/j.pupt.2008.01.008.
  19. Wright JL, Churg A. Animal models of cigarette smoke-induced COPD. Chest 2002;122:301s–306s. doi: 10.1378/chest.122.6_-suppl.301s.
  20. Mahadeva R, Shapiro SD. Chronic obstructive pulmonary disease ∗ 3: Experimental animal models of pulmonary emphysema. Thorax 2002;57:908–914. doi: 10.1136/thorax.57.10.908.
  21. Brusselle GG, Bracke KR, Maes T, D’Hulst AI, Moerloose KB, Joos GF, et al. Murine models of COPD. Pulm Pharmacol Ther 2006;19:155–165. doi: 10.1016/j.pupt.2005.06.001.
  22. Martin JG, Tamaoka M. Rat models of asthma and chronic obstructive lung disease. Pulm Pharmacol Ther 2006;19:377–385. doi: 10.1016/j.pupt.2005.10.005.
  23. Snider GL, Lucey EC, Faris B, Junglegg Y, Stone PJ, Franzblau C. Cadmium-Chloride-induced air-space enlargement with interstitial pulmonary fibrosis is not associated with destruction of lung elastin: implications for the pathogenesis of human emphysema. Am Rev Respir Dis 1988;137:918–923. doi: 10.1164/ajrccm/137.4.918.
  24. Kai MB, Beier J, Kornmann O, Mander A, Buhl R. Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD. Chest 2003;123:778–783. doi: 10.1378/chest.123.3.778.
  25. Rahman I, Morrison D, Donaldson K, Macnee W. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996;154:1055–1060. doi: 10.1164/ajrccm.154.4.8887607.
  26. Soodaeva S, Klimanov I, Li T, Boldina M, Postnikova L, Kubysheva N. Production of proinflammation cytokines and mean pulmonary arterial pressure in COPD. 2013. Available from: https://erj.ersjournals.com/content/42/Suppl_57/P643.article-info. [Accessed July 25, 2019].
  27. Hashimoto M, Tanaka H, Abe S. Quantitative analysis of bronchial wall vascularity in the medium and small airways of patients with asthma and COPD. Chest 2005;127:965–972. doi: 10.1378/chest.127.3.965.
  28. Gelb AF, Hogg JC, MüLler NL, Schein MJ, Kuei J, Tashkin DP, et al. Contribution of Emphysema and Small Airways in COPD. Chest 1996;109:353–359. doi: 10.1378/chest.109.2.353.
  29. Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest 2010;137:39S–51S. doi: 10.1378/chest.10-0087.
  30. Li N, Ouyang BS, Liu L, Lin CS, Xing DD, Liu J. Dexmedetomidine protected COPD-induced lung injury by regulating miRNA-146a. Bratisl Lek Listy 2016;117:539–542. doi: 10.4149/BLL_2016_106.
  31. Lopes FD, Toledo AC, Olivo CR, Prado CM, Leick EA, Medeiros MC, et al. A comparative study of extracellular matrix remodeling in two murine models of emphysema. Histol Histopathol 2013;28:269–276. doi: 10.14670/HH-28.269.
  32. D’Ambrosio D, Mariani M, Panina-Bordignon P, Sinigaglia F. Chemokines and their receptors guiding T lymphocyte recruitment in lung inflammation. Am J Respir Crit Care Med 2001;164:1266–1275. doi: 10.1164/ajrccm.164.7.2103011.
  33. Fahy JV, Corry DB, Boushey HA. Airway inflammation and remodeling in asthma. Curr Opin Pulm Med 2001;6:15–20. doi: 10.1097/00063198-200001000-00004

Was this helpful?

0 / 0